1013-00006 · Client 1013 · Internal Memoranda

indemnification-risk-allocation-memo.docx DOCUMENT M&A / Corporate

23 / 37 ← → ✕

MEMORANDUM

PRIVILEGED & CONFIDENTIAL ATTORNEY WORK PRODUCT

TO: James Prentice, Partner; Sandra Tung, Partner; Andrew Fitzpatrick, Associate

FROM: Tiffany Rosenthal, Lead Associate, M&A

DATE: May 14, 2023

RE: Indemnification and Risk Allocation Analysis — Divestiture of OncuPath™ Companion Diagnostics Assay Line by Genome Dx Therapeutics Inc. to Meridian Precision Diagnostics, Inc.

Matter No.: 1013-00006&A-4471

Client: Genome Dx Therapeutics Inc.

I. Executive Summary

The purpose of this memorandum is to provide a comprehensive analysis of the final indemnification and risk allocation framework embodied in the executed Asset Purchase Agreement, dated as of May 11, 2023 (the "APA"), by and between Genome Dx Therapeutics Inc., a Delaware corporation ("GDT" or "Seller"), and Meridian Precision Diagnostics, Inc., a Delaware corporation ("Meridian" or "Buyer"), pursuant to which Seller has agreed to sell substantially all of the assets exclusively related to the OncuPath™ companion diagnostics assay line (the "OncuPath Business") for aggregate consideration of One Hundred Forty Million Dollars ($140,000,000), consisting of One Hundred Twenty-Six Million Dollars ($126,000,000) in cash payable at closing (the "Closing Cash") and up to Fourteen Million Dollars ($14,000,000) in contingent earnout payments (the "Earnout").

The indemnification package negotiated in the APA reflects the following principal features:

• Aggregate Cap: Twenty percent (20%) of Total Consideration, or $28,000,000, applicable to all indemnifiable losses arising from breach of Seller's non-fundamental representations, warranties, covenants, and obligations.

• General Survival Period: Eighteen (18) months from the Closing Date, resulting in an expiration date of February 8, 2025 (assuming an August 8, 2023 closing).

• Aggregate Basket: $1,400,000 (1.0% of Total Consideration), structured as a tipping basket (dollar-one liability once the threshold is exceeded).

• De Minimis Threshold: $75,000 per individual claim, below which losses are excluded entirely and do not aggregate toward the basket.

• Escrow: $14,000,000 deposited at closing with Ashgrove Equity Partners Escrow Services, Inc., subject to a two-tranche release schedule — 50% at twelve (12) months post-closing and the remaining balance at eighteen (18) months post-closing (co-terminus with general survival expiration).

• Fundamental Representations Survival: Sixty (60) months from closing, extending through August 8, 2028, and not subject to the $28,000,000 cap or $1,400,000 basket.

The indemnification framework operates in conjunction with a buyer-side representations and warranties insurance policy (the "RWI Policy") issued by Apex Mutual Insurance Company under Policy No. RWI-2023-07182, providing $28,000,000 in coverage with a $1,400,000 retention, the premium for which was split equally between the parties. The RWI Policy materially reduces Seller's practical post-closing indemnification exposure by directing Buyer's primary recourse for covered representation and warranty breaches to the insurer rather than to Seller or the escrow.

Overall Assessment: The indemnification and risk allocation package is, on balance, favorable to Seller and consistent with — and in several respects better than — current market practice for biotech and diagnostics asset divestitures in the $100 million to $250 million range. Key Seller-protective features include: (a) the tipping basket structure, which, when combined with the 1.0% threshold, creates a meaningful screen against nuisance claims; (b) capped aggregate exposure at $28,000,000 for non-fundamental claims; (c) the 18-month general survival period, which represents the shorter end of the market range; (d) the two-tranche escrow release mechanism, which accelerates return of $7,000,000 to Seller at the 12-month mark; and (e) the contractual obligation on Buyer to first seek recovery under the RWI Policy before pursuing claims against Seller for covered matters. Seller's residual risk exposure is manageable and is largely within Seller's capacity to control through careful compliance with covenants, comprehensive and accurate disclosure schedules, and diligent execution of transition obligations under the Transition Services Agreement.

II. Transaction Overview

A. The Parties

Seller. Genome Dx Therapeutics Inc. ("GDT") is a Delaware corporation headquartered at 10250 Science Center Drive, Suite 600, San Diego, California 92121. GDT is a developer and commercializer of genomic profiling assays used in oncology and related precision medicine applications. For the fiscal year ended December 31, 2022, GDT reported total revenue of approximately $312,000,000, of which the OncuPath companion diagnostics line contributed approximately $47,600,000, representing approximately 15.3% of GDT's consolidated revenues. GDT's principal products outside the OncuPath line include the GenoStrat™ liquid biopsy platform, which is not part of the Purchased Assets and is being retained by Seller.

Equity Sponsor. Pinnacle Biosciences Partners Fund III, L.P. ("Pinnacle") holds approximately 68.4% of GDT's outstanding common stock and is the controlling equity sponsor. The Managing Partners of the general partner of Pinnacle are Nathaniel Hargrove, who also serves as Chairman of GDT's Board of Directors, and Priya Ramanathan. Pinnacle is not a party to the APA and has no direct indemnification obligations thereunder; its exposure to the transaction is limited to its indirect equity interest in GDT and its interest in the prompt distribution of net sale proceeds to the fund and its limited partners.

Buyer. Meridian Precision Diagnostics, Inc. ("Meridian") is a Delaware corporation headquartered at 2400 Meridian Parkway, Suite 300, Durham, North Carolina 27713. Meridian is a publicly traded diagnostics company with established capabilities in companion diagnostics, molecular pathology, and laboratory-developed tests. For the fiscal year ended December 31, 2022, Meridian reported revenue of approximately $589,000,000 and EBITDA of approximately $104,000,000. Meridian's acquisition of the OncuPath Business is expected to complement its existing oncology diagnostics portfolio and extend its FDA-cleared product offerings.

B. Transaction Structure

The transaction is structured as an asset purchase. The Purchased Assets include all assets, intellectual property, contracts, inventory, equipment, regulatory filings (including FDA 510(k) clearances and the pending PMA supplement), books and records, and goodwill exclusively related to the OncuPath companion diagnostics assay line. The Excluded Assets, which are retained by Seller, include the GenoStrat™ liquid biopsy platform and all related assets, GDT's corporate cash and cash equivalents (other than amounts included in closing working capital), pre-closing tax refunds, and GDT's corporate name, logos, and trademarks outside the OncuPath brand family. The asset purchase structure is significant from an indemnification perspective because it avoids the transfer of entity-level liabilities and allows for a cleaner delineation of assumed and excluded liabilities, though the carve-out nature of the transaction introduces complexities around shared-services allocation, intercompany arrangements, and the accurate preparation of carve-out financial statements.

C. Consideration. Total Consideration: $140,000,000, allocated as follows:

• Closing Cash: $126,000,000, payable at closing by wire transfer of immediately available funds, subject to customary purchase price adjustments for working capital, indebtedness, and transaction expenses.

• Earnout: Up to $14,000,000 in contingent milestone payments, structured as follows:

Milestone 1: $8,000,000, payable upon FDA clearance or approval of the OncuPath-HER3™ companion diagnostic assay on or before August 8, 2025 (24 months post-closing).

Milestone 2: $6,000,000, payable upon the establishment of a CMS HCPCS code and the receipt of first Medicare reimbursement for OncuPath-HER3™ on or before August 8, 2026 (36 months post-closing).

The earnout structure is analyzed in detail in the separate Earnout Structure Memorandum prepared by the deal team and is not the primary focus of this analysis, except to the extent that the earnout is included in Total Consideration for purposes of calculating the indemnification cap and basket percentages.

D. Key Advisors

The following advisors have been engaged in connection with the transaction:

Buyer's acquisition financing consists of a $95,000,000 senior secured term loan commitment from Summit National Bank, N.A. The lender's diligence and documentation requirements have been addressed by Buyer's counsel and are not a direct concern for Seller, except to the extent that Buyer's financing condition was eliminated as a closing condition (the APA does not contain a financing contingency).

E. Governing Law and Key Dates

The APA is governed by the laws of the State of Delaware, without regard to conflicts of law principles. The APA was executed on May 11, 2023. The target closing date was August 1, 2023; actual closing occurred on August 8, 2023 (the "Closing Date"), the one-week delay attributable to the completion of final HSR Act clearance and receipt of the Vantage Molecular Sciences license consent. All survival period calculations in this memorandum are based on the actual Closing Date of August 8, 2023.

III. Indemnification Cap

A. Aggregate Cap on Seller's Liability

Pursuant to Section 10.4(a) of the APA, Seller's aggregate indemnification liability for all Losses arising from or related to breaches of Seller's non-fundamental representations, warranties, covenants, and obligations under the APA is capped at twenty percent (20%) of Total Consideration, calculated as follows:

$140,000,000 × 20% = $28,000,000

This cap applies to all indemnifiable Losses without distinction as to the nature or type of representation, warranty, or covenant breached, provided that the breach relates to a non-fundamental representation or warranty or to a covenant. The cap operates as a ceiling on Seller's aggregate exposure and is reduced dollar-for-dollar by amounts previously paid or released from escrow in satisfaction of prior indemnification claims.

Importantly, the Fundamental Representations (discussed in Section VII below) are not subject to the $28,000,000 cap. However, Section 10.4(b) of the APA provides that Seller's aggregate liability for all claims — including both non-fundamental and Fundamental Representation claims — shall in no event exceed an amount equal to the Total Consideration of $140,000,000. This outer-limit cap effectively ensures that Seller's maximum theoretical exposure does not exceed the aggregate purchase price received, which is consistent with the general principle that an asset seller should not be required to disgorge more than the proceeds it received.

B. Market Benchmarking — Cap Analysis

To assess the reasonableness and market-consistency of the 20% cap, we surveyed publicly available data and proprietary deal databases for fifteen (15) comparable biotech and diagnostics asset divestitures completed between 2021 and 2023 in the $100 million to $250 million range. The detailed results of this survey are set forth in Appendix A to this memorandum. Key observations regarding the indemnification cap include:

• The median indemnification cap in comparable deals was in the range of 15% to 20% of enterprise value, with the most common cap at approximately 15% to 17%.

• Seller's negotiated 20% cap is at the upper end of the observed market range but remains within typical bounds. This is attributable in part to the carve-out nature of the transaction (which inherently presents greater risk to Buyer due to shared-services dependencies and the potential for incomplete asset separation) and in part to the regulated FDA/CLIA environment in which the OncuPath Business operates, which introduces additional compliance and regulatory risk that Buyer sought to address through a somewhat higher cap.

• During the markup process, Buyer initially proposed an indemnification cap of 25% of Total Consideration ($35,000,000). Seller's counter-proposal was 15% ($21,000,000). The parties reached agreement at 20% ($28,000,000) during the negotiation round reflected in the issues list dated April 14, 2023. The 20% cap was a key negotiation point and was ultimately accepted by Seller in conjunction with Seller's success in obtaining the 18-month general survival period (down from Buyer's initial 24-month request) and the two-tranche escrow release structure.

The 20% cap is appropriate and defensible in light of: (a) the asset purchase structure, which does not involve the transfer of entity-level risks; (b) the carve-out nature of the transaction, which presents potential shared-services allocation complexities that could give rise to post-closing claims; and (c) the FDA-regulated and CLIA-certified environment, which creates an overlay of regulatory compliance risk beyond what is typical in a non-regulated asset transaction.

C. Exclusions from Cap

The following categories of claims are not subject to the $28,000,000 cap (though they remain subject to the Total Consideration cap of $140,000,000, except in the case of fraud):

• Fraud. Claims arising from Seller's actual fraud (as defined in the APA to require intentional misrepresentation with knowledge of falsity and intent to deceive) are not subject to any cap, basket, de minimis threshold, or survival period limitation. Seller's liability for fraud is unlimited under the APA, consistent with Delaware law, which generally holds that contractual limitations on liability do not apply to claims sounding in fraud.

• Specific Indemnities. The APA does not include any separately negotiated specific indemnities for identified pre-closing liabilities. During the negotiation process, Buyer considered requesting a specific indemnity for potential exposure arising from the pending PMA supplement (P230014) for OncuPath-HER3™, but this was ultimately not pursued in light of the comprehensive regulatory disclosures in the Disclosure Schedules and the inclusion of this matter as a known-matters exclusion under the RWI Policy.

IV. Survival Periods

A. General Representations and Warranties

Pursuant to Section 10.1(a) of the APA, all representations and warranties of Seller contained in the APA (other than the Fundamental Representations, Tax Representations, and Environmental Representations, which are addressed separately below) survive the Closing for a period of eighteen (18) months from the Closing Date. Based on the actual Closing Date of August 8, 2023, the general representations and warranties survive through February 8, 2025.

To preserve a claim under the general representations and warranties, Buyer must deliver written notice of the claim to Seller specifying the nature of the breach, the factual basis for the claim, and a good-faith estimate of the amount of Losses (to the extent reasonably determinable) prior to the expiration of the survival period. Any claim properly asserted by written notice delivered before the expiration of the survival period will survive until its final resolution, regardless of whether such resolution occurs after the survival period has expired. However, any representation or warranty for which no claim has been asserted prior to the expiration of the survival period will terminate and be of no further force or effect, and no claim may thereafter be brought with respect thereto.

Market Comparison. The 18-month general survival period is consistent with the lower end of the 18- to 24-month range observed in comparable transactions surveyed for this analysis. Approximately 35% of the comparable deals used an 18-month general survival period, while approximately 50% used a 24-month period, and the remaining 15% used periods between 12 and 18 months. Buyer's initial position in the term sheet and first draft of the APA was a 24-month general survival period. Seller successfully negotiated the period down to 18 months during the markup process, which represents a meaningful concession by Buyer and is a favorable outcome for Seller. The shorter survival period reduces the window during which Buyer can assert indemnification claims for non-fundamental representation breaches and aligns the survival period with the final escrow release date, thereby facilitating a clean and prompt return of escrowed funds to Seller.

B. Fundamental Representations

The Fundamental Representations survive for a period of sixty (60) months from the Closing Date, extending through August 8, 2028. The Fundamental Representations are defined in Section 10.1(b) of the APA to include the following representations and warranties of Seller:

(i) Organization, Good Standing, and Qualification (Section 3.1);

(ii) Authority; Binding Agreement (Section 3.2);

(iii) No Conflicts; Required Consents (Section 3.3);

(iv) Title to Purchased Assets (Section 3.6);

(v) Brokers and Finders (Section 3.22); and

(vi) Capitalization (Section 3.4), to the extent relevant to the asset sale and the ownership of the Purchased Assets.

The Fundamental Representations are not subject to the $28,000,000 aggregate cap applicable to non-fundamental representations; instead, they are subject only to the Total Consideration cap of $140,000,000. They are also not subject to the $1,400,000 aggregate basket or the $75,000 per-claim de minimis threshold. Recovery for breaches of Fundamental Representations is not limited to the escrow; Buyer may pursue direct claims against Seller.

The 60-month survival period for Fundamental Representations is at the longer end of market practice, where the typical range is 36 to 72 months. Approximately 40% of surveyed deals used a 36- or 48-month survival for fundamental representations, while approximately 45% used a 60- or 72-month period. The 60-month period reflects the particular importance to Buyer of clear and unencumbered title to the Purchased Assets and intellectual property in a diagnostics carve-out, where the chain of title to a complex portfolio of patents, patent applications, trademarks, and licensed technology is critical to the value of the acquired business.

C. Special Representations

Tax Representations. The Tax Representations (Section 3.14 of the APA) survive until sixty (60) days after the expiration of the applicable statute of limitations (including any waivers, tolling agreements, or extensions thereof) for the relevant tax periods. This is a customary approach that ensures Tax Representations remain in effect for as long as the relevant taxing authority retains the ability to assess additional tax liability, plus a reasonable buffer period.

Environmental Representations. The Environmental Representations (Section 3.16 of the APA) survive for thirty-six (36) months from the Closing Date, or through approximately August 8, 2026. It is important to note, however, that environmental liabilities at GDT facilities that are not being conveyed as part of the Purchased Assets are Excluded Liabilities retained by Seller and are not within the scope of the indemnification provisions. The Environmental Representations relate to the environmental condition and compliance status of the specific facilities, equipment, and operations being transferred as part of the OncuPath Business, including the leased premises at 4820 Towne Centre Drive (laboratory operations) and 925 Industrial Court (warehouse and distribution).

D. Covenants. Pre-Closing Covenants. Seller's pre-closing covenants, including the interim operating covenants set forth in Section 5.1 of the APA (requiring Seller to operate the OncuPath Business in the ordinary course of business consistent with past practice during the period between signing and closing), survive for eighteen (18) months from the Closing Date, co-terminus with the general representations and warranties. This alignment simplifies the survival analysis and ensures that all pre-closing covenant claims must be asserted within the same window as general representation claims.

Post-Closing Covenants. Post-closing covenants (including non-competition, non-solicitation, cooperation with regulatory filings, and obligations under the Transition Services Agreement) survive in accordance with their respective terms as specified in the APA or, if no specific term is stated, for the applicable statute of limitations for contractual claims under Delaware law, which is generally three (3) years under 10 Del. C. § 8106.

V. Basket and De Minimis Threshold

A. Aggregate Basket (Tipping)

Section 10.4(c) of the APA establishes an aggregate basket of $1,400,000 (calculated as 1.0% of Total Consideration: $140,000,000 × 1.0% = $1,400,000). The basket is structured as a tipping basket (sometimes referred to as a "first dollar" basket): once the aggregate amount of indemnifiable Losses exceeds the $1,400,000 threshold, Seller becomes liable for the entire amount of such Losses from dollar one — not merely the amount in excess of the basket. In contrast, a "true deductible" basket would require Buyer to absorb the first $1,400,000 of Losses and would limit Seller's liability to the excess over that amount.

Market Observations. The tipping basket structure is generally regarded as more favorable to the indemnified party (in this case, Buyer) than a true deductible, because once the threshold is crossed, the indemnifying party bears the full amount of losses without any retained first-dollar exposure on the part of the indemnified party. Tipping baskets were used in approximately 60% of the comparable deals surveyed for this analysis, while true deductibles were used in approximately 40%. The 1.0% threshold is positioned at the mid-range of the 0.75% to 1.25% range observed in comparable transactions of this size.

Negotiation History. The basket structure and amount were a significant point of negotiation. Buyer initially proposed a 0.75% true deductible ($1,050,000), which would have set a lower threshold but with Buyer absorbing the initial tranche of losses. Seller's counter-proposal was a 1.25% tipping basket ($1,750,000), which would have set a higher threshold before any liability attached. The parties ultimately settled on a 1.0% tipping basket ($1,400,000), which represents a reasonable compromise: the tipping structure favors Buyer, while the 1.0% threshold (higher than Buyer's initial 0.75% proposal) provides Seller with a meaningful initial screen against smaller or aggregated claims. The net effect is that Buyer must accumulate at least $1,400,000 in qualifying Losses before Seller has any indemnification liability, but once that threshold is exceeded, Seller's liability commences from the first dollar.

B. De Minimis Threshold (Per Claim)

Section 10.4(d) of the APA establishes a de minimis threshold of $75,000 per individual claim or series of related claims. Losses attributable to any individual claim (or series of related claims arising from the same or substantially similar facts or circumstances) that do not exceed $75,000 are excluded entirely from the indemnification framework and do not count toward — or aggregate for purposes of — the $1,400,000 basket threshold.

The de minimis threshold serves two important functions: (a) it prevents the aggregation of numerous small, immaterial, or nuisance claims to exceed the basket threshold, thereby protecting Seller from death-by-a-thousand-cuts indemnification exposure; and (b) it promotes administrative efficiency by eliminating the need for both parties to incur the costs associated with investigating, documenting, and resolving de minimis claims.

Market Comparison. The $75,000 de minimis threshold is within the typical range of $50,000 to $150,000 for transactions of this size. It is positioned at the lower end of that range, which is somewhat less favorable to Seller than a higher de minimis would be, but is consistent with the overall balance of the negotiated indemnification package.

C. Exclusions from Basket and De Minimis

The following categories of claims are not subject to the basket or de minimis threshold:

(i) Fundamental Representations. Claims arising from breaches of the Fundamental Representations are not subject to the $1,400,000 basket or the $75,000 de minimis threshold. Any such claim, regardless of amount, may be asserted directly and is not required to aggregate with other claims before liability attaches.

(ii) Fraud. Claims arising from Seller's actual fraud are not subject to the basket or de minimis, consistent with the general exclusion of fraud claims from all contractual limitations on indemnification liability.

(iii) Specific Indemnities. Not applicable in this transaction, as no specific indemnities were negotiated.

VI. Escrow Mechanics

A. Escrow Deposit

Pursuant to Section 2.3(b) of the APA and the Escrow Agreement entered into concurrently with the APA among Seller, Buyer, and Ashgrove Equity Partners Escrow Services, Inc. (the "Escrow Agent"), an amount equal to $14,000,000 (representing 10% of Total Consideration: $140,000,000 × 10% = $14,000,000) was deposited at closing into a segregated escrow account maintained by the Escrow Agent. The relevant escrow account details are as follows:

Escrow Agent: Ashgrove Equity Partners Escrow Services, Inc.

Designated Officer: Samantha Koh, Vice President

Office Address: 101 California Street, Suite 1250, San Francisco, California 94111

Account Number: 8841-7023-5500

The escrow deposit was funded from the Closing Cash otherwise payable to Seller, such that Seller received $112,000,000 in immediately available funds at closing ($126,000,000 Closing Cash less the $14,000,000 escrow deposit), subject to customary purchase price adjustments for estimated working capital, indebtedness, and transaction expenses.

The escrow funds constitute the exclusive source of recovery for Buyer's indemnification claims during the escrow period, with limited but important exceptions: claims arising from fraud and claims based on breaches of Fundamental Representations are not limited to the escrow and may be pursued against Seller directly. This exclusive-remedy-during-escrow provision is a significant Seller protection, as it ensures that during the period in which the escrow is available, Buyer cannot simultaneously pursue direct claims against Seller for non-fundamental, non-fraud matters.

B. Two-Tranche Release Schedule

The Escrow Agreement provides for a two-tranche release of escrowed funds to Seller, structured as follows:

First Release — Twelve (12) Months Post-Closing (August 8, 2024). On the first anniversary of the Closing Date, fifty percent (50%) of the then-remaining escrow balance is released to Seller. If no indemnification claims are pending as of the first release date, this results in a release of $7,000,000. If one or more indemnification claims are pending but unresolved as of the first release date, the Escrow Agent will retain a Pending Claim Reserve equal to the aggregate amount of all pending but unresolved claims (as specified in the applicable claim notices), and the first release will be calculated as 50% of the remaining escrow balance net of the Pending Claim Reserve. For example, if $1,000,000 in claims are pending at the first release date, the Pending Claim Reserve would be $1,000,000, and the first release would be 50% × ($14,000,000 − $1,000,000) = $6,500,000.

Final Release — Eighteen (18) Months Post-Closing / Survival Period Expiration (February 8, 2025). On the date that is eighteen (18) months after the Closing Date (which is co-terminus with the expiration of the general representations and warranties survival period), the entire remaining escrow balance is released to Seller, net of any Pending Claim Reserve for indemnification claims that have been properly asserted by written notice delivered prior to the expiration of the survival period but that remain unresolved as of the final release date. Any amounts retained in escrow as a Pending Claim Reserve following the final release date will be released to Seller upon the resolution of the applicable claims, either by mutual agreement of the parties or by final determination pursuant to the dispute resolution provisions of the APA.

Market Comparison. The two-tranche escrow release structure is Seller-favorable relative to market practice. Approximately 55% of the comparable deals surveyed used a single escrow release at the expiration of the survival period, while approximately 35% used a two-tranche release (as in the GDT transaction), and the remaining 10% used three or more release tranches. The first-tranche release at 12 months accelerates the return of a significant portion of the escrowed funds to Seller — and, indirectly, to Pinnacle as the controlling equity sponsor — well before the expiration of the general survival period. This structure was a specific Seller negotiation priority, as Pinnacle sought to minimize the duration of capital lock-up and facilitate timely distributions to the fund's limited partners.

C. Claim Procedures

The Escrow Agreement and Section 10.5 of the APA establish the following procedures for the assertion and resolution of indemnification claims against the escrow:

(i) Claim Notice. Buyer asserts an indemnification claim by delivering written notice to Seller (with a copy to the Escrow Agent) specifying in reasonable detail: (a) the nature of the claim, including the specific representation, warranty, or covenant alleged to have been breached; (b) the factual basis for the claim; and (c) a good-faith estimate of the amount of Losses (to the extent reasonably determinable at the time of the notice).

(ii) Seller's Response. Seller has thirty (30) days from receipt of the claim notice to deliver a written response to Buyer (with a copy to the Escrow Agent) accepting the claim, objecting to the claim (in whole or in part), or requesting additional information. If Seller does not deliver a response within the 30-day period, Seller is deemed to have objected to the claim.

(iii) Agreed Claims. If Seller accepts a claim (or a portion thereof), the parties deliver joint written instructions to the Escrow Agent directing the release of the agreed amount from escrow to Buyer.

(iv) Disputed Claims. If a claim is disputed, the escrowed funds attributable to the disputed claim remain in escrow pending resolution through the APA's dispute resolution procedures, which provide for the exclusive jurisdiction of the Delaware Court of Chancery (or, if the Court of Chancery lacks subject matter jurisdiction, the Superior Court of the State of Delaware).

(v) Interest. Interest earned on escrowed funds is allocated to the party ultimately entitled to receive the underlying principal. Investment of escrowed funds is limited to obligations of the United States Treasury and institutional money market funds rated in the highest category by a nationally recognized rating agency, as specified in Section 4(a) of the Escrow Agreement.

D. Relationship Between Escrow and Indemnification Cap

The $14,000,000 escrow is a subset of the $28,000,000 aggregate indemnification cap. The escrow does not represent additional or incremental exposure beyond the cap; rather, it provides a pre-funded source of recovery for Buyer's initial indemnification claims, up to the $14,000,000 escrow balance.

For non-fundamental representation claims, Buyer's exclusive remedy during the escrow period is recourse to the escrow. Once the escrow is exhausted (or following the final release of escrow funds), Buyer may pursue direct claims against Seller for any remaining indemnification exposure up to the $28,000,000 aggregate cap. This structure effectively creates a two-tier recovery framework:

Tier 1 (Escrow-Funded Recovery): $0 — $14,000,000. Buyer's first recourse for non-fundamental, non-fraud indemnification claims is the escrow. Claims within this tier are satisfied from escrowed funds, subject to the claim procedures described above.

Tier 2 (Direct Claim Against Seller): $14,000,000 — $28,000,000. If Buyer's aggregate indemnifiable Losses exceed the escrow balance (or if the escrow has been fully released), Buyer may pursue direct claims against Seller for the incremental exposure, up to the $28,000,000 aggregate cap.

This two-tier structure provides Seller with the practical benefit of knowing that during the escrow period, its direct out-of-pocket exposure for covered claims is zero — all such claims are funded from the escrow. Seller's direct exposure arises only if aggregate claims exceed $14,000,000 (at which point the escrow would be exhausted) or if claims relate to Fundamental Representations or fraud (which are not limited to the escrow).

VII. Fundamental Representations — Special Treatment

The treatment of Fundamental Representations under the APA is summarized in the sections above and warrants a consolidated discussion given the significant differences from the treatment of general representations and warranties:

• Extended Survival: Sixty (60) months from the Closing Date, extending through August 8, 2028 — more than three times the 18-month general survival period.

• Not Subject to Aggregate Cap: Claims arising from breaches of Fundamental Representations are not subject to the $28,000,000 indemnification cap. They are subject only to the outer-limit Total Consideration cap of $140,000,000.

• Not Subject to Basket or De Minimis: Claims arising from breaches of Fundamental Representations are not subject to the $1,400,000 tipping basket or the $75,000 per-claim de minimis threshold. Any such claim, regardless of amount, may be asserted directly from the first dollar of loss.

• Recovery Not Limited to Escrow: Buyer may pursue direct claims against Seller for breaches of Fundamental Representations and is not required to first exhaust the escrow. This is consistent with the treatment of Fundamental Representations as a category of heightened importance warranting enhanced remedies.

Rationale. The enhanced treatment of Fundamental Representations reflects the heightened importance of these representations to the integrity of the transaction itself. The Fundamental Representations address the most foundational aspects of the deal: that Seller exists and is in good standing, that Seller has the corporate authority and power to consummate the transaction, that the transaction does not conflict with applicable law or other contractual obligations, that Seller has good and marketable title to the Purchased Assets free and clear of encumbrances (other than Permitted Liens), and that no broker or finder has been engaged in circumstances that could give rise to a fee or commission claim against Buyer. In a carve-out transaction involving complex intellectual property — here, 14 issued U.S. patents, 7 pending patent applications, and 3 registered trademarks, together with the exclusive license from Vantage Molecular Sciences, Inc. — and regulated diagnostic assets — including FDA 510(k) clearances K201847, K193215, and K210562, and CLIA certificate 05D2178493 — the representation regarding clear title to the Purchased Assets is particularly critical to the value proposition for Buyer.

Risk Assessment for Seller. While the 60-month survival period and uncapped exposure for Fundamental Representations are facially significant, Seller's actual risk profile with respect to these representations is manageable for several reasons. First, breaches of Fundamental Representations are relatively rare in practice and are typically within Seller's knowledge and control — Seller either has good standing, has authority, and has clear title, or it does not. Second, comprehensive intellectual property diligence was conducted during the transaction, including chain-of-title reviews for all patents and trademarks, freedom-to-operate analysis, and confirmation of the validity and assignability of the Vantage Molecular Sciences license. Third, the Disclosure Schedules provide a knowledge qualifier and exception mechanism that allows Seller to disclose known exceptions to the Fundamental Representations without triggering a breach. Fourth, the requirement that Buyer deliver written notice of a claim within the survival period, specifying the nature and factual basis of the alleged breach, provides a procedural safeguard that prevents stale or vague claims. Accordingly, while Seller should maintain robust documentation supporting the accuracy of the Fundamental Representations for the full 60-month survival period, the practical likelihood of a material Fundamental Representation claim is assessed as low.

VIII. Representations and Warranties Insurance — Interplay with Indemnification

A. Policy Overview

In connection with the transaction, a buyer-side representations and warranties insurance policy (the "RWI Policy") has been procured from Apex Mutual Insurance Company. The key terms of the RWI Policy are as follows:

The RWI Policy is a buyer-side policy, meaning that Buyer is the named insured and the policy provides coverage for Buyer's Losses arising from breaches of Seller's representations and warranties. The policy limit of $28,000,000 is intentionally aligned with the APA indemnification cap, so that the RWI Policy provides dollar-for-dollar backup coverage for Buyer's contractual indemnification rights under the APA. The retention of $1,400,000 is aligned with the APA aggregate basket, meaning that the policy will not respond until Buyer's Losses exceed $1,400,000 — the same threshold at which Seller's contractual indemnification obligation is triggered under the tipping basket.

B. Impact on Seller's Risk Profile

The RWI Policy significantly reduces Seller's practical indemnification exposure. Because the policy is buyer-side and provides Buyer with a well-capitalized, creditworthy source of recovery for representation and warranty breaches, Buyer's primary recourse for covered claims will be against Apex Mutual rather than against Seller or the escrow. This dynamic is reinforced by the contractual obligation in Section 10.8 of the APA requiring Buyer to first seek recovery under the RWI Policy before pursuing indemnification claims against Seller for matters covered by the policy.

As a practical matter, this means that for the vast majority of indemnification claims — i.e., those arising from breaches of non-fundamental representations that are not excluded as known matters and that do not involve fraud — Seller's direct exposure is effectively limited to:

(i) Claims within the $1,400,000 retention. The RWI Policy retention ($1,400,000) is aligned with the APA basket ($1,400,000), so Buyer must satisfy both the contractual basket and the policy retention before Apex Mutual has any obligation to respond. For claims within the retention, Buyer would look to the escrow (or, after escrow release, directly to Seller) for recovery. However, because the basket is a tipping basket, Buyer would need to demonstrate aggregate Losses in excess of $1,400,000 before Seller has any liability, at which point the RWI Policy would also become active above the retention. As a result, the practical scenario in which Seller bears exposure within the retention but the RWI Policy does not respond is limited to situations where aggregate Losses are between $0 and $1,400,000 — in which case neither Seller (under the tipping basket) nor Apex Mutual (under the retention) would be liable.

(ii) Known-matters exclusions. Claims related to matters identified as known matters during the underwriting process are excluded from RWI coverage. Seller bears direct exposure for these claims, subject to the APA's cap, basket, and survival period.

(iii) Fraud and intentional misrepresentation. Claims arising from Seller's actual fraud or intentional misrepresentation are excluded from RWI coverage, consistent with industry practice. Seller's exposure for fraud claims is unlimited under the APA.

(iv) Claims exceeding the $28,000,000 policy limit. Theoretically, if aggregate Losses exceeded $28,000,000, Buyer could pursue Seller for the excess. However, because the APA cap for non-fundamental representations also equals $28,000,000, this scenario would arise only in the context of Fundamental Representation claims (which are subject only to the $140,000,000 Total Consideration cap). For Fundamental Representation claims exceeding the RWI Policy limit, Buyer could pursue Seller directly for amounts between $28,000,000 and $140,000,000.

C. Known-Matters Exclusions

During the underwriting process, Apex Mutual's underwriting team (led by Philip Aldridge, SVP) reviewed the data room materials, diligence reports, and the no-claims declaration provided by Seller's management. Based on this review, the following known matters were excluded from coverage under the RWI Policy:

(i) Pending OncuPath-HER3™ PMA Supplement. The pending PMA supplement (P230014), submitted to the FDA on January 30, 2023, seeking approval of the OncuPath-HER3™ companion diagnostic assay, presents an uncertain regulatory outcome. Any Losses arising from the denial, withdrawal, or adverse outcome of this PMA supplement are excluded from RWI coverage. This exclusion is particularly relevant because Milestone 1 of the Earnout ($8,000,000) is conditioned on FDA clearance or approval of OncuPath-HER3™, and a denial of the PMA supplement could give rise to disputes under the earnout provisions (though earnout disputes are addressed under a separate provision of the APA and are not indemnification claims per se).

(ii) Pre-Closing Litigation Matters. Any pre-closing litigation matters disclosed in the Disclosure Schedules are excluded from RWI coverage. As of the date of this memorandum, the Disclosure Schedules identify two pending litigation matters: (a) a patent infringement claim asserted by NovaBio Diagnostics Corp. (Case No. 3:22-cv-01847, U.S. District Court for the Southern District of California), and (b) a wage-and-hour class action by former OncuPath laboratory technicians (Case No. 37-2023-00009812-CU-OE-CTL, San Diego Superior Court). Both matters are disclosed in Schedule 3.11 and are Excluded Liabilities.

(iii) Working Capital Adjustment Disputes. Any disputes arising from the post-closing working capital adjustment mechanism are excluded from RWI coverage, as the NWC adjustment is a price adjustment mechanism rather than a representation and warranty claim.

Seller Awareness. Seller should be aware that any indemnification claims related to the above known matters will fall outside the protection of the RWI Policy and will be borne directly by Seller, subject to the applicable cap, basket, and survival period limitations under the APA. To the extent that any of these known matters give rise to indemnification exposure, Seller's risk mitigation strategy should focus on the comprehensive nature of the Disclosure Schedule disclosures and the argument that adequate disclosure of these matters precludes a breach of the applicable representations.

D. Premium Cost-Sharing Rationale

The $840,000 RWI premium was split equally between Seller and Buyer, with each party bearing $420,000 (50%). This 50/50 cost-sharing arrangement is typical in transactions where the RWI Policy benefits both parties: Buyer obtains an additional, well-capitalized source of recovery for indemnification claims beyond the escrow and the cap, while Seller benefits from the reduced likelihood that Buyer will pursue direct claims against Seller or draw on the escrow for covered matters. The premium cost-sharing also reflects the economic reality that the RWI Policy was a component of the overall deal construct — Seller's agreement to share in the premium cost was part of the negotiation that produced the 18-month survival period, 20% cap, and two-tranche escrow release.

Seller's $420,000 share of the RWI premium is treated as a transaction cost and is reflected in the closing funds flow, reducing the net cash proceeds received by Seller at closing.

E. Coordination Between RWI and Escrow

The interaction between the RWI Policy and the escrow mechanics is designed to minimize Seller's direct indemnification exposure:

During the Escrow Period (Closing through February 8, 2025). Section 10.8 of the APA requires Buyer to first tender indemnification claims to Apex Mutual under the RWI Policy before drawing on the escrow for covered matters. This "insurance-first" provision is a critical Seller protection that preserves the escrow balance and maximizes the likelihood that escrowed funds will be returned to Seller at the scheduled release dates. If Apex Mutual accepts and pays a claim, the escrow is not affected. If Apex Mutual denies a claim (e.g., due to a known-matters exclusion or a coverage dispute), Buyer may then seek recovery from the escrow, subject to the claim procedures and dispute resolution mechanisms described in Section VI.C above.

Post-Escrow Release (After February 8, 2025). Following the final release of escrowed funds, Buyer's sole recourse for covered claims is the RWI Policy (up to the $28,000,000 limit), and for uncovered claims (including known matters and fraud), direct claims against Seller (subject to the APA's post-survival limitations). For non-fundamental representation claims, the survival period will have expired by the time of the final escrow release, so no new claims may be asserted after that date. For Fundamental Representation claims, which survive for 60 months, Buyer retains recourse to the RWI Policy (which also covers Fundamental Representations for 60 months) and, for matters excluded from or exceeding RWI coverage, direct claims against Seller.

This coordination structure is expected to result in minimal or no actual draws on the escrow, which is a significant practical benefit to Seller and Pinnacle. The equity sponsor's interest in prompt return of sale proceeds to the fund — particularly in light of the fund's anticipated distribution timeline — is well-served by the combination of the two-tranche escrow release and the insurance-first requirement that diverts covered claims to Apex Mutual rather than to the escrow.

IX. Assumed Liabilities vs. Excluded Liabilities — Risk Boundary

A. Assumed Liabilities

Pursuant to Section 2.4 of the APA, Buyer assumes the following liabilities in connection with the acquisition of the OncuPath Business (the "Assumed Liabilities"):

(i) All trade payables and other current liabilities of the OncuPath Business arising or accruing in the ordinary course of business from and after the Closing Date;

(ii) All obligations arising under the Assumed Contracts from and after the Closing Date, including but not limited to: (a) the exclusive technology license agreement with Vantage Molecular Sciences, Inc. dated September 12, 2019 (as amended, the "Vantage License"); (b) all transferred customer and supplier contracts identified on Schedule 2.1(e) to the APA; and (c) the assigned leases for the premises located at 4820 Towne Centre Drive, San Diego, California (laboratory operations) and 925 Industrial Court, San Diego, California (warehouse and distribution);

(iii) All product warranty claims and product liability obligations for OncuPath assays shipped or distributed on or after the Closing Date; and

(iv) All other liabilities and obligations arising out of or relating to Buyer's ownership or operation of the OncuPath Business from and after the Closing Date.

Seller has no indemnification obligation with respect to the Assumed Liabilities. Any losses or claims arising from Assumed Liabilities are Buyer's sole responsibility, and Buyer has agreed to indemnify and hold harmless Seller with respect thereto under Section 10.3 of the APA.

B. Excluded Liabilities (Retained by Seller)

Section 2.5 of the APA identifies the following liabilities as "Excluded Liabilities," which are retained by Seller and are not assumed by Buyer:

(i) All liabilities of the OncuPath Business arising, accruing, or relating to the period prior to the Closing Date, including trade payables, accrued expenses, and other obligations that are attributable to the pre-closing operation of the OncuPath Business (except to the extent reflected as current liabilities in the closing working capital calculation);

(ii) Any litigation, claims, or proceedings pending as of the Closing Date, including the NovaBio patent infringement action and the wage-and-hour class action identified in the Disclosure Schedules;

(iii) All employee benefit obligations (including severance, COBRA, accrued paid time off, and pension or retirement plan obligations) with respect to the five (5) OncuPath employees who did not accept offers of employment from Buyer (of the 83 employees who received offers, 78 accepted and 5 declined). GDT retains all obligations with respect to the non-transferring employees;

(iv) All environmental liabilities at GDT facilities that are not being conveyed as part of the Purchased Assets, including any remediation, cleanup, or compliance obligations at GDT's corporate headquarters or other retained facilities;

(v) All pre-closing tax liabilities of GDT attributable to the OncuPath Business, including income taxes, employment taxes, sales and use taxes, and any other taxes arising from or related to the operation of the OncuPath Business prior to the Closing Date; and

(vi) All other liabilities and obligations of GDT that are not Assumed Liabilities.

Seller's indemnification obligations under Section 10.2 of the APA encompass the Excluded Liabilities to the extent that any Excluded Liability is inadvertently transferred to, imposed upon, or otherwise affects Buyer in connection with the transaction. This creates a contractual backstop ensuring that if an Excluded Liability "follows" the assets to Buyer notwithstanding the parties' intention to retain such liability with Seller, Buyer has recourse to Seller's indemnification for the resulting Losses.

The clear delineation of Assumed and Excluded Liabilities is fundamental to the risk boundary between the parties. Seller should ensure that the closing funds flow and working capital calculations accurately reflect the allocation of pre-closing and post-closing liabilities, as any misallocation could give rise to indemnification claims or working capital adjustment disputes.

X. Working Capital Adjustment — Interaction with Indemnification

The APA includes a customary post-closing working capital adjustment mechanism, the key terms of which are as follows:

• Target Net Working Capital ("NWC"): $6,800,000, determined by reference to the carve-out financial statements of the OncuPath Business prepared by Haverford & Lane LLP for the twelve-month period ended December 31, 2022, and the stub period ended March 31, 2023.

• Collar: ±$350,000. No purchase price adjustment is made if final NWC falls within the collar range of $6,450,000 to $7,150,000. If final NWC is above $7,150,000, the purchase price is increased by the amount of the excess. If final NWC is below $6,450,000, the purchase price is decreased by the amount of the shortfall.

• True-Up Deadline: The final NWC determination must be completed within ninety (90) days of the Closing Date, or by November 6, 2023.

• Dispute Resolution: If the parties cannot agree on the final NWC within thirty (30) days of Seller's delivery of an objection notice, the disputed items are submitted to a mutually agreed independent accounting firm for binding determination. The costs of the independent accounting firm are allocated between the parties based on the relative success of their respective positions.

Interaction with Indemnification Framework. The NWC adjustment is expressly characterized in the APA as a price adjustment mechanism and is not an indemnification claim. Accordingly, the NWC adjustment is carved out from the indemnification cap, basket, and de minimis threshold. This means that a dollar-for-dollar adjustment to the purchase price based on the final NWC calculation is not subject to the $1,400,000 basket, the $75,000 de minimis, or the $28,000,000 cap. This carve-out is standard and reflects the fundamental distinction between purchase price mechanics (which are designed to ensure that Buyer pays, and Seller receives, the appropriate price based on the financial condition of the business at closing) and indemnification (which addresses breaches of representations, warranties, and covenants).

Risk Note. Working capital disputes are common in carve-out transactions due to the inherent complexity of allocating shared costs, intercompany charges, and corporate overhead between the divested business and the retained business. In the OncuPath transaction, several line items in the NWC calculation involve allocations of shared IT infrastructure costs, shared facility expenses, and centralized HR/payroll costs that were historically borne at the GDT corporate level and allocated to the OncuPath Business based on methodologies that may be subject to differing interpretations. Haverford & Lane's preparation of the carve-out financial statements and its involvement in the final closing balance sheet provide Seller with a credible, independent basis for its NWC position in the event of a dispute. Nevertheless, Seller should anticipate the possibility of a working capital dispute and ensure that all allocation methodologies are well-documented and consistent with the accounting principles specified in the APA (which reference GAAP applied on a basis consistent with the preparation of the carve-out financial statements).

XI. Benchmarking Against Comparable Biotech Asset Divestitures

A. Methodology. To assess the market-consistency and relative favorability of the indemnification package negotiated in the GDT/Meridian APA, we reviewed publicly available data (including SEC filings, industry surveys published by the American Bar Association's Private Target Mergers & Acquisitions Deal Points Study, and the Cascade Advisory Group M&A Deal Terms Study) and proprietary deal databases maintained by Calderwood & Harkness for fifteen (15) comparable biotech and diagnostics asset divestitures completed between 2021 and 2023 in the $100 million to $250 million range. The detailed results of this survey are set forth in Appendix A. The following key indemnification metrics were compared: indemnification cap as a percentage of deal value, survival period for general and fundamental representations, basket type (tipping vs. true deductible) and amount as a percentage of deal value, de minimis threshold, escrow amount as a percentage of deal value, RWI usage and policy limits, and escrow release structure.

B. Summary Comparison Table

The following table summarizes the benchmarking analysis:

C. Overall Assessment

The negotiated indemnification package is well-positioned from Seller's perspective. The most significant Seller-favorable features are: (a) the 18-month general survival period, which is at the shortest end of the observed market range and provides a compressed window for Buyer to assert claims; (b) the two-tranche escrow release, which accelerates the return of $7,000,000 to Seller at the 12-month mark rather than requiring Seller to wait until survival expiration; and (c) the buyer-side RWI Policy, which serves as Buyer's primary recourse for covered claims and reduces the practical likelihood that Buyer will pursue direct claims against Seller or the escrow.

The 20% indemnification cap, while at the upper end of the market range, is substantially mitigated by the RWI Policy. Because Buyer is contractually required to tender covered claims to Apex Mutual before seeking recovery from Seller, the effective cap from Seller's perspective is functionally lower than 20% for the vast majority of potential claims. The 1.0% tipping basket and $75,000 de minimis threshold are within market norms and provide reasonable first-dollar protection for Seller.

Taken as a whole, the indemnification package reflects a balanced outcome that is consistent with — and in several respects superior to — the indemnification terms observed in comparable biotech and diagnostics asset divestitures in this size range.

XII. Seller-Specific Risk Considerations

A. Carve-Out Complexity

The OncuPath Business is being carved out of GDT's broader operations, which introduces a number of complexities that could give rise to post-closing indemnification claims or disputes. During the pre-closing period and for up to nine (9) months following the Closing, GDT will provide Meridian with certain transitional support services pursuant to the Transition Services Agreement (the "TSA"), including IT infrastructure and systems support, HR and payroll administration, facilities management, and shared laboratory equipment access. Services under the TSA are provided at cost plus a five percent (5%) administrative markup.

The TSA creates potential friction points that could give rise to breach-of-covenant claims under the APA. In particular, disputes may arise regarding: (a) the quality or timeliness of services provided; (b) the methodology for calculating "cost" and the application of the 5% markup; (c) allocation of shared expenses between the OncuPath Business and GDT's retained operations; and (d) the timeline and process for transitioning services to Meridian's own systems and personnel.

Recommendation: Seller should implement strict internal tracking of all TSA costs, service levels, and performance metrics from the inception of the TSA. Detailed contemporaneous records will be essential to defending against any post-closing claims that GDT failed to perform its TSA obligations in a commercially reasonable manner or that GDT overcharged for transition services.

B. Regulatory Risk

The Purchased Assets include three FDA-cleared 510(k) companion diagnostic assays (K201847, K193215, and K210562) and a pending PMA supplement (P230014) for the OncuPath-HER3™ companion diagnostic assay. Additionally, the OncuPath laboratory operations are conducted under CLIA certificate 05D2178493. Post-closing regulatory issues relating to pre-closing manufacturing, marketing, or laboratory practices could give rise to indemnification claims. Potential scenarios include:

(i) FDA warning letters or inspection findings referencing pre-closing manufacturing practices or quality system deficiencies;

(ii) Product recalls or field safety corrective actions for assays manufactured and shipped prior to closing;

(iii) CMS enforcement actions related to pre-closing laboratory testing practices or CLIA compliance; and

(iv) State regulatory actions in any of the states in which the OncuPath Business holds clinical laboratory permits.

Mitigation: Seller has made comprehensive regulatory disclosures in Schedules 3.15 and 3.16 of the Disclosure Schedules, including a complete list of FDA clearances and submissions, CLIA certificates and permits, and a summary of the most recent FDA and CLIA inspection results. The 18-month general survival period limits the window during which Buyer may assert claims based on pre-closing regulatory matters (other than those captured by the Fundamental Representations or the 36-month Environmental Representations survival). Seller's regulatory compliance team should ensure that all pre-closing regulatory filings, inspection records, and corrective action plans are comprehensive and accurately reflected in the Disclosure Schedules.

C. Intellectual Property

The transfer of intellectual property is a critical component of the transaction. The Purchased Assets include 14 issued U.S. patents, 7 pending patent applications, and 3 registered trademarks, as well as associated trade secrets, know-how, and proprietary data. The IP representations in the APA (Section 3.10) address ownersh

MEMORANDUM
PRIVILEGED & CONFIDENTIAL ATTORNEY WORK PRODUCT
TO: James Prentice, Partner; Sandra Tung, Partner; Andrew Fitzpatrick, Associate
FROM: Tiffany Rosenthal, Lead Associate, M&A
DATE: May 14, 2023
RE: Indemnification and Risk Allocation Analysis — Divestiture of OncuPath™ Companion Diagnostics Assay Line by Genome Dx Therapeutics Inc. to Meridian Precision Diagnostics, Inc.
Matter No.: 1013-00006&A-4471
Client: Genome Dx Therapeutics Inc.
I. Executive Summary
The purpose of this memorandum is to provide a comprehensive analysis of the final indemnification and risk allocation framework embodied in the executed Asset Purchase Agreement, dated as of May 11, 2023 (the "APA"), by and between Genome Dx Therapeutics Inc., a Delaware corporation ("GDT" or "Seller"), and Meridian Precision Diagnostics, Inc., a Delaware corporation ("Meridian" or "Buyer"), pursuant to which Seller has agreed to sell substantially all of the assets exclusively related to the OncuPath™ companion diagnostics assay line (the "OncuPath Business") for aggregate consideration of One Hundred Forty Million Dollars ($140,000,000), consisting of One Hundred Twenty-Six Million Dollars ($126,000,000) in cash payable at closing (the "Closing Cash") and up to Fourteen Million Dollars ($14,000,000) in contingent earnout payments (the "Earnout").
The indemnification package negotiated in the APA reflects the following principal features:
• Aggregate Cap: Twenty percent (20%) of Total Consideration, or $28,000,000, applicable to all indemnifiable losses arising from breach of Seller's non-fundamental representations, warranties, covenants, and obligations.
• General Survival Period: Eighteen (18) months from the Closing Date, resulting in an expiration date of February 8, 2025 (assuming an August 8, 2023 closing).
• Aggregate Basket: $1,400,000 (1.0% of Total Consideration), structured as a tipping basket (dollar-one liability once the threshold is exceeded).
• De Minimis Threshold: $75,000 per individual claim, below which losses are excluded entirely and do not aggregate toward the basket.
• Escrow: $14,000,000 deposited at closing with Ashgrove Equity Partners Escrow Services, Inc., subject to a two-tranche release schedule — 50% at twelve (12) months post-closing and the remaining balance at eighteen (18) months post-closing (co-terminus with general survival expiration).
• Fundamental Representations Survival: Sixty (60) months from closing, extending through August 8, 2028, and not subject to the $28,000,000 cap or $1,400,000 basket.
The indemnification framework operates in conjunction with a buyer-side representations and warranties insurance policy (the "RWI Policy") issued by Apex Mutual Insurance Company under Policy No. RWI-2023-07182, providing $28,000,000 in coverage with a $1,400,000 retention, the premium for which was split equally between the parties. The RWI Policy materially reduces Seller's practical post-closing indemnification exposure by directing Buyer's primary recourse for covered representation and warranty breaches to the insurer rather than to Seller or the escrow.
Overall Assessment: The indemnification and risk allocation package is, on balance, favorable to Seller and consistent with — and in several respects better than — current market practice for biotech and diagnostics asset divestitures in the $100 million to $250 million range. Key Seller-protective features include: (a) the tipping basket structure, which, when combined with the 1.0% threshold, creates a meaningful screen against nuisance claims; (b) capped aggregate exposure at $28,000,000 for non-fundamental claims; (c) the 18-month general survival period, which represents the shorter end of the market range; (d) the two-tranche escrow release mechanism, which accelerates return of $7,000,000 to Seller at the 12-month mark; and (e) the contractual obligation on Buyer to first seek recovery under the RWI Policy before pursuing claims against Seller for covered matters. Seller's residual risk exposure is manageable and is largely within Seller's capacity to control through careful compliance with covenants, comprehensive and accurate disclosure schedules, and diligent execution of transition obligations under the Transition Services Agreement.
II. Transaction Overview
A. The Parties
Seller. Genome Dx Therapeutics Inc. ("GDT") is a Delaware corporation headquartered at 10250 Science Center Drive, Suite 600, San Diego, California 92121. GDT is a developer and commercializer of genomic profiling assays used in oncology and related precision medicine applications. For the fiscal year ended December 31, 2022, GDT reported total revenue of approximately $312,000,000, of which the OncuPath companion diagnostics line contributed approximately $47,600,000, representing approximately 15.3% of GDT's consolidated revenues. GDT's principal products outside the OncuPath line include the GenoStrat™ liquid biopsy platform, which is not part of the Purchased Assets and is being retained by Seller.
Equity Sponsor. Pinnacle Biosciences Partners Fund III, L.P. ("Pinnacle") holds approximately 68.4% of GDT's outstanding common stock and is the controlling equity sponsor. The Managing Partners of the general partner of Pinnacle are Nathaniel Hargrove, who also serves as Chairman of GDT's Board of Directors, and Priya Ramanathan. Pinnacle is not a party to the APA and has no direct indemnification obligations thereunder; its exposure to the transaction is limited to its indirect equity interest in GDT and its interest in the prompt distribution of net sale proceeds to the fund and its limited partners.
Buyer. Meridian Precision Diagnostics, Inc. ("Meridian") is a Delaware corporation headquartered at 2400 Meridian Parkway, Suite 300, Durham, North Carolina 27713. Meridian is a publicly traded diagnostics company with established capabilities in companion diagnostics, molecular pathology, and laboratory-developed tests. For the fiscal year ended December 31, 2022, Meridian reported revenue of approximately $589,000,000 and EBITDA of approximately $104,000,000. Meridian's acquisition of the OncuPath Business is expected to complement its existing oncology diagnostics portfolio and extend its FDA-cleared product offerings.
B. Transaction Structure
The transaction is structured as an asset purchase. The Purchased Assets include all assets, intellectual property, contracts, inventory, equipment, regulatory filings (including FDA 510(k) clearances and the pending PMA supplement), books and records, and goodwill exclusively related to the OncuPath companion diagnostics assay line. The Excluded Assets, which are retained by Seller, include the GenoStrat™ liquid biopsy platform and all related assets, GDT's corporate cash and cash equivalents (other than amounts included in closing working capital), pre-closing tax refunds, and GDT's corporate name, logos, and trademarks outside the OncuPath brand family. The asset purchase structure is significant from an indemnification perspective because it avoids the transfer of entity-level liabilities and allows for a cleaner delineation of assumed and excluded liabilities, though the carve-out nature of the transaction introduces complexities around shared-services allocation, intercompany arrangements, and the accurate preparation of carve-out financial statements.
C. Consideration. Total Consideration: $140,000,000, allocated as follows:
• Closing Cash: $126,000,000, payable at closing by wire transfer of immediately available funds, subject to customary purchase price adjustments for working capital, indebtedness, and transaction expenses.
• Earnout: Up to $14,000,000 in contingent milestone payments, structured as follows:
Milestone 1: $8,000,000, payable upon FDA clearance or approval of the OncuPath-HER3™ companion diagnostic assay on or before August 8, 2025 (24 months post-closing).
Milestone 2: $6,000,000, payable upon the establishment of a CMS HCPCS code and the receipt of first Medicare reimbursement for OncuPath-HER3™ on or before August 8, 2026 (36 months post-closing).
The earnout structure is analyzed in detail in the separate Earnout Structure Memorandum prepared by the deal team and is not the primary focus of this analysis, except to the extent that the earnout is included in Total Consideration for purposes of calculating the indemnification cap and basket percentages.
D. Key Advisors
The following advisors have been engaged in connection with the transaction:
Buyer's acquisition financing consists of a $95,000,000 senior secured term loan commitment from Summit National Bank, N.A. The lender's diligence and documentation requirements have been addressed by Buyer's counsel and are not a direct concern for Seller, except to the extent that Buyer's financing condition was eliminated as a closing condition (the APA does not contain a financing contingency).
E. Governing Law and Key Dates
The APA is governed by the laws of the State of Delaware, without regard to conflicts of law principles. The APA was executed on May 11, 2023. The target closing date was August 1, 2023; actual closing occurred on August 8, 2023 (the "Closing Date"), the one-week delay attributable to the completion of final HSR Act clearance and receipt of the Vantage Molecular Sciences license consent. All survival period calculations in this memorandum are based on the actual Closing Date of August 8, 2023.
III. Indemnification Cap
A. Aggregate Cap on Seller's Liability
Pursuant to Section 10.4(a) of the APA, Seller's aggregate indemnification liability for all Losses arising from or related to breaches of Seller's non-fundamental representations, warranties, covenants, and obligations under the APA is capped at twenty percent (20%) of Total Consideration, calculated as follows:
$140,000,000 × 20% = $28,000,000
This cap applies to all indemnifiable Losses without distinction as to the nature or type of representation, warranty, or covenant breached, provided that the breach relates to a non-fundamental representation or warranty or to a covenant. The cap operates as a ceiling on Seller's aggregate exposure and is reduced dollar-for-dollar by amounts previously paid or released from escrow in satisfaction of prior indemnification claims.
Importantly, the Fundamental Representations (discussed in Section VII below) are not subject to the $28,000,000 cap. However, Section 10.4(b) of the APA provides that Seller's aggregate liability for all claims — including both non-fundamental and Fundamental Representation claims — shall in no event exceed an amount equal to the Total Consideration of $140,000,000. This outer-limit cap effectively ensures that Seller's maximum theoretical exposure does not exceed the aggregate purchase price received, which is consistent with the general principle that an asset seller should not be required to disgorge more than the proceeds it received.
B. Market Benchmarking — Cap Analysis
To assess the reasonableness and market-consistency of the 20% cap, we surveyed publicly available data and proprietary deal databases for fifteen (15) comparable biotech and diagnostics asset divestitures completed between 2021 and 2023 in the $100 million to $250 million range. The detailed results of this survey are set forth in Appendix A to this memorandum. Key observations regarding the indemnification cap include:
• The median indemnification cap in comparable deals was in the range of 15% to 20% of enterprise value, with the most common cap at approximately 15% to 17%.
• Seller's negotiated 20% cap is at the upper end of the observed market range but remains within typical bounds. This is attributable in part to the carve-out nature of the transaction (which inherently presents greater risk to Buyer due to shared-services dependencies and the potential for incomplete asset separation) and in part to the regulated FDA/CLIA environment in which the OncuPath Business operates, which introduces additional compliance and regulatory risk that Buyer sought to address through a somewhat higher cap.
• During the markup process, Buyer initially proposed an indemnification cap of 25% of Total Consideration ($35,000,000). Seller's counter-proposal was 15% ($21,000,000). The parties reached agreement at 20% ($28,000,000) during the negotiation round reflected in the issues list dated April 14, 2023. The 20% cap was a key negotiation point and was ultimately accepted by Seller in conjunction with Seller's success in obtaining the 18-month general survival period (down from Buyer's initial 24-month request) and the two-tranche escrow release structure.
The 20% cap is appropriate and defensible in light of: (a) the asset purchase structure, which does not involve the transfer of entity-level risks; (b) the carve-out nature of the transaction, which presents potential shared-services allocation complexities that could give rise to post-closing claims; and (c) the FDA-regulated and CLIA-certified environment, which creates an overlay of regulatory compliance risk beyond what is typical in a non-regulated asset transaction.
C. Exclusions from Cap
The following categories of claims are not subject to the $28,000,000 cap (though they remain subject to the Total Consideration cap of $140,000,000, except in the case of fraud):
• Fraud. Claims arising from Seller's actual fraud (as defined in the APA to require intentional misrepresentation with knowledge of falsity and intent to deceive) are not subject to any cap, basket, de minimis threshold, or survival period limitation. Seller's liability for fraud is unlimited under the APA, consistent with Delaware law, which generally holds that contractual limitations on liability do not apply to claims sounding in fraud.
• Specific Indemnities. The APA does not include any separately negotiated specific indemnities for identified pre-closing liabilities. During the negotiation process, Buyer considered requesting a specific indemnity for potential exposure arising from the pending PMA supplement (P230014) for OncuPath-HER3™, but this was ultimately not pursued in light of the comprehensive regulatory disclosures in the Disclosure Schedules and the inclusion of this matter as a known-matters exclusion under the RWI Policy.
IV. Survival Periods
A. General Representations and Warranties
Pursuant to Section 10.1(a) of the APA, all representations and warranties of Seller contained in the APA (other than the Fundamental Representations, Tax Representations, and Environmental Representations, which are addressed separately below) survive the Closing for a period of eighteen (18) months from the Closing Date. Based on the actual Closing Date of August 8, 2023, the general representations and warranties survive through February 8, 2025.
To preserve a claim under the general representations and warranties, Buyer must deliver written notice of the claim to Seller specifying the nature of the breach, the factual basis for the claim, and a good-faith estimate of the amount of Losses (to the extent reasonably determinable) prior to the expiration of the survival period. Any claim properly asserted by written notice delivered before the expiration of the survival period will survive until its final resolution, regardless of whether such resolution occurs after the survival period has expired. However, any representation or warranty for which no claim has been asserted prior to the expiration of the survival period will terminate and be of no further force or effect, and no claim may thereafter be brought with respect thereto.
Market Comparison. The 18-month general survival period is consistent with the lower end of the 18- to 24-month range observed in comparable transactions surveyed for this analysis. Approximately 35% of the comparable deals used an 18-month general survival period, while approximately 50% used a 24-month period, and the remaining 15% used periods between 12 and 18 months. Buyer's initial position in the term sheet and first draft of the APA was a 24-month general survival period. Seller successfully negotiated the period down to 18 months during the markup process, which represents a meaningful concession by Buyer and is a favorable outcome for Seller. The shorter survival period reduces the window during which Buyer can assert indemnification claims for non-fundamental representation breaches and aligns the survival period with the final escrow release date, thereby facilitating a clean and prompt return of escrowed funds to Seller.
B. Fundamental Representations
The Fundamental Representations survive for a period of sixty (60) months from the Closing Date, extending through August 8, 2028. The Fundamental Representations are defined in Section 10.1(b) of the APA to include the following representations and warranties of Seller:
(i) Organization, Good Standing, and Qualification (Section 3.1);
(ii) Authority; Binding Agreement (Section 3.2);
(iii) No Conflicts; Required Consents (Section 3.3);
(iv) Title to Purchased Assets (Section 3.6);
(v) Brokers and Finders (Section 3.22); and
(vi) Capitalization (Section 3.4), to the extent relevant to the asset sale and the ownership of the Purchased Assets.
The Fundamental Representations are not subject to the $28,000,000 aggregate cap applicable to non-fundamental representations; instead, they are subject only to the Total Consideration cap of $140,000,000. They are also not subject to the $1,400,000 aggregate basket or the $75,000 per-claim de minimis threshold. Recovery for breaches of Fundamental Representations is not limited to the escrow; Buyer may pursue direct claims against Seller.
The 60-month survival period for Fundamental Representations is at the longer end of market practice, where the typical range is 36 to 72 months. Approximately 40% of surveyed deals used a 36- or 48-month survival for fundamental representations, while approximately 45% used a 60- or 72-month period. The 60-month period reflects the particular importance to Buyer of clear and unencumbered title to the Purchased Assets and intellectual property in a diagnostics carve-out, where the chain of title to a complex portfolio of patents, patent applications, trademarks, and licensed technology is critical to the value of the acquired business.
C. Special Representations
Tax Representations. The Tax Representations (Section 3.14 of the APA) survive until sixty (60) days after the expiration of the applicable statute of limitations (including any waivers, tolling agreements, or extensions thereof) for the relevant tax periods. This is a customary approach that ensures Tax Representations remain in effect for as long as the relevant taxing authority retains the ability to assess additional tax liability, plus a reasonable buffer period.
Environmental Representations. The Environmental Representations (Section 3.16 of the APA) survive for thirty-six (36) months from the Closing Date, or through approximately August 8, 2026. It is important to note, however, that environmental liabilities at GDT facilities that are not being conveyed as part of the Purchased Assets are Excluded Liabilities retained by Seller and are not within the scope of the indemnification provisions. The Environmental Representations relate to the environmental condition and compliance status of the specific facilities, equipment, and operations being transferred as part of the OncuPath Business, including the leased premises at 4820 Towne Centre Drive (laboratory operations) and 925 Industrial Court (warehouse and distribution).
D. Covenants. Pre-Closing Covenants. Seller's pre-closing covenants, including the interim operating covenants set forth in Section 5.1 of the APA (requiring Seller to operate the OncuPath Business in the ordinary course of business consistent with past practice during the period between signing and closing), survive for eighteen (18) months from the Closing Date, co-terminus with the general representations and warranties. This alignment simplifies the survival analysis and ensures that all pre-closing covenant claims must be asserted within the same window as general representation claims.
Post-Closing Covenants. Post-closing covenants (including non-competition, non-solicitation, cooperation with regulatory filings, and obligations under the Transition Services Agreement) survive in accordance with their respective terms as specified in the APA or, if no specific term is stated, for the applicable statute of limitations for contractual claims under Delaware law, which is generally three (3) years under 10 Del. C. § 8106.
V. Basket and De Minimis Threshold
A. Aggregate Basket (Tipping)
Section 10.4(c) of the APA establishes an aggregate basket of $1,400,000 (calculated as 1.0% of Total Consideration: $140,000,000 × 1.0% = $1,400,000). The basket is structured as a tipping basket (sometimes referred to as a "first dollar" basket): once the aggregate amount of indemnifiable Losses exceeds the $1,400,000 threshold, Seller becomes liable for the entire amount of such Losses from dollar one — not merely the amount in excess of the basket. In contrast, a "true deductible" basket would require Buyer to absorb the first $1,400,000 of Losses and would limit Seller's liability to the excess over that amount.
Market Observations. The tipping basket structure is generally regarded as more favorable to the indemnified party (in this case, Buyer) than a true deductible, because once the threshold is crossed, the indemnifying party bears the full amount of losses without any retained first-dollar exposure on the part of the indemnified party. Tipping baskets were used in approximately 60% of the comparable deals surveyed for this analysis, while true deductibles were used in approximately 40%. The 1.0% threshold is positioned at the mid-range of the 0.75% to 1.25% range observed in comparable transactions of this size.
Negotiation History. The basket structure and amount were a significant point of negotiation. Buyer initially proposed a 0.75% true deductible ($1,050,000), which would have set a lower threshold but with Buyer absorbing the initial tranche of losses. Seller's counter-proposal was a 1.25% tipping basket ($1,750,000), which would have set a higher threshold before any liability attached. The parties ultimately settled on a 1.0% tipping basket ($1,400,000), which represents a reasonable compromise: the tipping structure favors Buyer, while the 1.0% threshold (higher than Buyer's initial 0.75% proposal) provides Seller with a meaningful initial screen against smaller or aggregated claims. The net effect is that Buyer must accumulate at least $1,400,000 in qualifying Losses before Seller has any indemnification liability, but once that threshold is exceeded, Seller's liability commences from the first dollar.
B. De Minimis Threshold (Per Claim)
Section 10.4(d) of the APA establishes a de minimis threshold of $75,000 per individual claim or series of related claims. Losses attributable to any individual claim (or series of related claims arising from the same or substantially similar facts or circumstances) that do not exceed $75,000 are excluded entirely from the indemnification framework and do not count toward — or aggregate for purposes of — the $1,400,000 basket threshold.
The de minimis threshold serves two important functions: (a) it prevents the aggregation of numerous small, immaterial, or nuisance claims to exceed the basket threshold, thereby protecting Seller from death-by-a-thousand-cuts indemnification exposure; and (b) it promotes administrative efficiency by eliminating the need for both parties to incur the costs associated with investigating, documenting, and resolving de minimis claims.
Market Comparison. The $75,000 de minimis threshold is within the typical range of $50,000 to $150,000 for transactions of this size. It is positioned at the lower end of that range, which is somewhat less favorable to Seller than a higher de minimis would be, but is consistent with the overall balance of the negotiated indemnification package.
C. Exclusions from Basket and De Minimis
The following categories of claims are not subject to the basket or de minimis threshold:
(i) Fundamental Representations. Claims arising from breaches of the Fundamental Representations are not subject to the $1,400,000 basket or the $75,000 de minimis threshold. Any such claim, regardless of amount, may be asserted directly and is not required to aggregate with other claims before liability attaches.
(ii) Fraud. Claims arising from Seller's actual fraud are not subject to the basket or de minimis, consistent with the general exclusion of fraud claims from all contractual limitations on indemnification liability.
(iii) Specific Indemnities. Not applicable in this transaction, as no specific indemnities were negotiated.
VI. Escrow Mechanics
A. Escrow Deposit
Pursuant to Section 2.3(b) of the APA and the Escrow Agreement entered into concurrently with the APA among Seller, Buyer, and Ashgrove Equity Partners Escrow Services, Inc. (the "Escrow Agent"), an amount equal to $14,000,000 (representing 10% of Total Consideration: $140,000,000 × 10% = $14,000,000) was deposited at closing into a segregated escrow account maintained by the Escrow Agent. The relevant escrow account details are as follows:
Escrow Agent: Ashgrove Equity Partners Escrow Services, Inc.
Designated Officer: Samantha Koh, Vice President
Office Address: 101 California Street, Suite 1250, San Francisco, California 94111
Account Number: 8841-7023-5500
The escrow deposit was funded from the Closing Cash otherwise payable to Seller, such that Seller received $112,000,000 in immediately available funds at closing ($126,000,000 Closing Cash less the $14,000,000 escrow deposit), subject to customary purchase price adjustments for estimated working capital, indebtedness, and transaction expenses.
The escrow funds constitute the exclusive source of recovery for Buyer's indemnification claims during the escrow period, with limited but important exceptions: claims arising from fraud and claims based on breaches of Fundamental Representations are not limited to the escrow and may be pursued against Seller directly. This exclusive-remedy-during-escrow provision is a significant Seller protection, as it ensures that during the period in which the escrow is available, Buyer cannot simultaneously pursue direct claims against Seller for non-fundamental, non-fraud matters.
B. Two-Tranche Release Schedule
The Escrow Agreement provides for a two-tranche release of escrowed funds to Seller, structured as follows:
First Release — Twelve (12) Months Post-Closing (August 8, 2024). On the first anniversary of the Closing Date, fifty percent (50%) of the then-remaining escrow balance is released to Seller. If no indemnification claims are pending as of the first release date, this results in a release of $7,000,000. If one or more indemnification claims are pending but unresolved as of the first release date, the Escrow Agent will retain a Pending Claim Reserve equal to the aggregate amount of all pending but unresolved claims (as specified in the applicable claim notices), and the first release will be calculated as 50% of the remaining escrow balance net of the Pending Claim Reserve. For example, if $1,000,000 in claims are pending at the first release date, the Pending Claim Reserve would be $1,000,000, and the first release would be 50% × ($14,000,000 − $1,000,000) = $6,500,000.
Final Release — Eighteen (18) Months Post-Closing / Survival Period Expiration (February 8, 2025). On the date that is eighteen (18) months after the Closing Date (which is co-terminus with the expiration of the general representations and warranties survival period), the entire remaining escrow balance is released to Seller, net of any Pending Claim Reserve for indemnification claims that have been properly asserted by written notice delivered prior to the expiration of the survival period but that remain unresolved as of the final release date. Any amounts retained in escrow as a Pending Claim Reserve following the final release date will be released to Seller upon the resolution of the applicable claims, either by mutual agreement of the parties or by final determination pursuant to the dispute resolution provisions of the APA.
Market Comparison. The two-tranche escrow release structure is Seller-favorable relative to market practice. Approximately 55% of the comparable deals surveyed used a single escrow release at the expiration of the survival period, while approximately 35% used a two-tranche release (as in the GDT transaction), and the remaining 10% used three or more release tranches. The first-tranche release at 12 months accelerates the return of a significant portion of the escrowed funds to Seller — and, indirectly, to Pinnacle as the controlling equity sponsor — well before the expiration of the general survival period. This structure was a specific Seller negotiation priority, as Pinnacle sought to minimize the duration of capital lock-up and facilitate timely distributions to the fund's limited partners.
C. Claim Procedures
The Escrow Agreement and Section 10.5 of the APA establish the following procedures for the assertion and resolution of indemnification claims against the escrow:
(i) Claim Notice. Buyer asserts an indemnification claim by delivering written notice to Seller (with a copy to the Escrow Agent) specifying in reasonable detail: (a) the nature of the claim, including the specific representation, warranty, or covenant alleged to have been breached; (b) the factual basis for the claim; and (c) a good-faith estimate of the amount of Losses (to the extent reasonably determinable at the time of the notice).
(ii) Seller's Response. Seller has thirty (30) days from receipt of the claim notice to deliver a written response to Buyer (with a copy to the Escrow Agent) accepting the claim, objecting to the claim (in whole or in part), or requesting additional information. If Seller does not deliver a response within the 30-day period, Seller is deemed to have objected to the claim.
(iii) Agreed Claims. If Seller accepts a claim (or a portion thereof), the parties deliver joint written instructions to the Escrow Agent directing the release of the agreed amount from escrow to Buyer.
(iv) Disputed Claims. If a claim is disputed, the escrowed funds attributable to the disputed claim remain in escrow pending resolution through the APA's dispute resolution procedures, which provide for the exclusive jurisdiction of the Delaware Court of Chancery (or, if the Court of Chancery lacks subject matter jurisdiction, the Superior Court of the State of Delaware).
(v) Interest. Interest earned on escrowed funds is allocated to the party ultimately entitled to receive the underlying principal. Investment of escrowed funds is limited to obligations of the United States Treasury and institutional money market funds rated in the highest category by a nationally recognized rating agency, as specified in Section 4(a) of the Escrow Agreement.
D. Relationship Between Escrow and Indemnification Cap
The $14,000,000 escrow is a subset of the $28,000,000 aggregate indemnification cap. The escrow does not represent additional or incremental exposure beyond the cap; rather, it provides a pre-funded source of recovery for Buyer's initial indemnification claims, up to the $14,000,000 escrow balance.
For non-fundamental representation claims, Buyer's exclusive remedy during the escrow period is recourse to the escrow. Once the escrow is exhausted (or following the final release of escrow funds), Buyer may pursue direct claims against Seller for any remaining indemnification exposure up to the $28,000,000 aggregate cap. This structure effectively creates a two-tier recovery framework:
Tier 1 (Escrow-Funded Recovery): $0 — $14,000,000. Buyer's first recourse for non-fundamental, non-fraud indemnification claims is the escrow. Claims within this tier are satisfied from escrowed funds, subject to the claim procedures described above.
Tier 2 (Direct Claim Against Seller): $14,000,000 — $28,000,000. If Buyer's aggregate indemnifiable Losses exceed the escrow balance (or if the escrow has been fully released), Buyer may pursue direct claims against Seller for the incremental exposure, up to the $28,000,000 aggregate cap.
This two-tier structure provides Seller with the practical benefit of knowing that during the escrow period, its direct out-of-pocket exposure for covered claims is zero — all such claims are funded from the escrow. Seller's direct exposure arises only if aggregate claims exceed $14,000,000 (at which point the escrow would be exhausted) or if claims relate to Fundamental Representations or fraud (which are not limited to the escrow).
VII. Fundamental Representations — Special Treatment
The treatment of Fundamental Representations under the APA is summarized in the sections above and warrants a consolidated discussion given the significant differences from the treatment of general representations and warranties:
• Extended Survival: Sixty (60) months from the Closing Date, extending through August 8, 2028 — more than three times the 18-month general survival period.
• Not Subject to Aggregate Cap: Claims arising from breaches of Fundamental Representations are not subject to the $28,000,000 indemnification cap. They are subject only to the outer-limit Total Consideration cap of $140,000,000.
• Not Subject to Basket or De Minimis: Claims arising from breaches of Fundamental Representations are not subject to the $1,400,000 tipping basket or the $75,000 per-claim de minimis threshold. Any such claim, regardless of amount, may be asserted directly from the first dollar of loss.
• Recovery Not Limited to Escrow: Buyer may pursue direct claims against Seller for breaches of Fundamental Representations and is not required to first exhaust the escrow. This is consistent with the treatment of Fundamental Representations as a category of heightened importance warranting enhanced remedies.
Rationale. The enhanced treatment of Fundamental Representations reflects the heightened importance of these representations to the integrity of the transaction itself. The Fundamental Representations address the most foundational aspects of the deal: that Seller exists and is in good standing, that Seller has the corporate authority and power to consummate the transaction, that the transaction does not conflict with applicable law or other contractual obligations, that Seller has good and marketable title to the Purchased Assets free and clear of encumbrances (other than Permitted Liens), and that no broker or finder has been engaged in circumstances that could give rise to a fee or commission claim against Buyer. In a carve-out transaction involving complex intellectual property — here, 14 issued U.S. patents, 7 pending patent applications, and 3 registered trademarks, together with the exclusive license from Vantage Molecular Sciences, Inc. — and regulated diagnostic assets — including FDA 510(k) clearances K201847, K193215, and K210562, and CLIA certificate 05D2178493 — the representation regarding clear title to the Purchased Assets is particularly critical to the value proposition for Buyer.
Risk Assessment for Seller. While the 60-month survival period and uncapped exposure for Fundamental Representations are facially significant, Seller's actual risk profile with respect to these representations is manageable for several reasons. First, breaches of Fundamental Representations are relatively rare in practice and are typically within Seller's knowledge and control — Seller either has good standing, has authority, and has clear title, or it does not. Second, comprehensive intellectual property diligence was conducted during the transaction, including chain-of-title reviews for all patents and trademarks, freedom-to-operate analysis, and confirmation of the validity and assignability of the Vantage Molecular Sciences license. Third, the Disclosure Schedules provide a knowledge qualifier and exception mechanism that allows Seller to disclose known exceptions to the Fundamental Representations without triggering a breach. Fourth, the requirement that Buyer deliver written notice of a claim within the survival period, specifying the nature and factual basis of the alleged breach, provides a procedural safeguard that prevents stale or vague claims. Accordingly, while Seller should maintain robust documentation supporting the accuracy of the Fundamental Representations for the full 60-month survival period, the practical likelihood of a material Fundamental Representation claim is assessed as low.
VIII. Representations and Warranties Insurance — Interplay with Indemnification
A. Policy Overview
In connection with the transaction, a buyer-side representations and warranties insurance policy (the "RWI Policy") has been procured from Apex Mutual Insurance Company. The key terms of the RWI Policy are as follows:
The RWI Policy is a buyer-side policy, meaning that Buyer is the named insured and the policy provides coverage for Buyer's Losses arising from breaches of Seller's representations and warranties. The policy limit of $28,000,000 is intentionally aligned with the APA indemnification cap, so that the RWI Policy provides dollar-for-dollar backup coverage for Buyer's contractual indemnification rights under the APA. The retention of $1,400,000 is aligned with the APA aggregate basket, meaning that the policy will not respond until Buyer's Losses exceed $1,400,000 — the same threshold at which Seller's contractual indemnification obligation is triggered under the tipping basket.
B. Impact on Seller's Risk Profile
The RWI Policy significantly reduces Seller's practical indemnification exposure. Because the policy is buyer-side and provides Buyer with a well-capitalized, creditworthy source of recovery for representation and warranty breaches, Buyer's primary recourse for covered claims will be against Apex Mutual rather than against Seller or the escrow. This dynamic is reinforced by the contractual obligation in Section 10.8 of the APA requiring Buyer to first seek recovery under the RWI Policy before pursuing indemnification claims against Seller for matters covered by the policy.
As a practical matter, this means that for the vast majority of indemnification claims — i.e., those arising from breaches of non-fundamental representations that are not excluded as known matters and that do not involve fraud — Seller's direct exposure is effectively limited to:
(i) Claims within the $1,400,000 retention. The RWI Policy retention ($1,400,000) is aligned with the APA basket ($1,400,000), so Buyer must satisfy both the contractual basket and the policy retention before Apex Mutual has any obligation to respond. For claims within the retention, Buyer would look to the escrow (or, after escrow release, directly to Seller) for recovery. However, because the basket is a tipping basket, Buyer would need to demonstrate aggregate Losses in excess of $1,400,000 before Seller has any liability, at which point the RWI Policy would also become active above the retention. As a result, the practical scenario in which Seller bears exposure within the retention but the RWI Policy does not respond is limited to situations where aggregate Losses are between $0 and $1,400,000 — in which case neither Seller (under the tipping basket) nor Apex Mutual (under the retention) would be liable.
(ii) Known-matters exclusions. Claims related to matters identified as known matters during the underwriting process are excluded from RWI coverage. Seller bears direct exposure for these claims, subject to the APA's cap, basket, and survival period.
(iii) Fraud and intentional misrepresentation. Claims arising from Seller's actual fraud or intentional misrepresentation are excluded from RWI coverage, consistent with industry practice. Seller's exposure for fraud claims is unlimited under the APA.
(iv) Claims exceeding the $28,000,000 policy limit. Theoretically, if aggregate Losses exceeded $28,000,000, Buyer could pursue Seller for the excess. However, because the APA cap for non-fundamental representations also equals $28,000,000, this scenario would arise only in the context of Fundamental Representation claims (which are subject only to the $140,000,000 Total Consideration cap). For Fundamental Representation claims exceeding the RWI Policy limit, Buyer could pursue Seller directly for amounts between $28,000,000 and $140,000,000.
C. Known-Matters Exclusions
During the underwriting process, Apex Mutual's underwriting team (led by Philip Aldridge, SVP) reviewed the data room materials, diligence reports, and the no-claims declaration provided by Seller's management. Based on this review, the following known matters were excluded from coverage under the RWI Policy:
(i) Pending OncuPath-HER3™ PMA Supplement. The pending PMA supplement (P230014), submitted to the FDA on January 30, 2023, seeking approval of the OncuPath-HER3™ companion diagnostic assay, presents an uncertain regulatory outcome. Any Losses arising from the denial, withdrawal, or adverse outcome of this PMA supplement are excluded from RWI coverage. This exclusion is particularly relevant because Milestone 1 of the Earnout ($8,000,000) is conditioned on FDA clearance or approval of OncuPath-HER3™, and a denial of the PMA supplement could give rise to disputes under the earnout provisions (though earnout disputes are addressed under a separate provision of the APA and are not indemnification claims per se).
(ii) Pre-Closing Litigation Matters. Any pre-closing litigation matters disclosed in the Disclosure Schedules are excluded from RWI coverage. As of the date of this memorandum, the Disclosure Schedules identify two pending litigation matters: (a) a patent infringement claim asserted by NovaBio Diagnostics Corp. (Case No. 3:22-cv-01847, U.S. District Court for the Southern District of California), and (b) a wage-and-hour class action by former OncuPath laboratory technicians (Case No. 37-2023-00009812-CU-OE-CTL, San Diego Superior Court). Both matters are disclosed in Schedule 3.11 and are Excluded Liabilities.
(iii) Working Capital Adjustment Disputes. Any disputes arising from the post-closing working capital adjustment mechanism are excluded from RWI coverage, as the NWC adjustment is a price adjustment mechanism rather than a representation and warranty claim.
Seller Awareness. Seller should be aware that any indemnification claims related to the above known matters will fall outside the protection of the RWI Policy and will be borne directly by Seller, subject to the applicable cap, basket, and survival period limitations under the APA. To the extent that any of these known matters give rise to indemnification exposure, Seller's risk mitigation strategy should focus on the comprehensive nature of the Disclosure Schedule disclosures and the argument that adequate disclosure of these matters precludes a breach of the applicable representations.
D. Premium Cost-Sharing Rationale
The $840,000 RWI premium was split equally between Seller and Buyer, with each party bearing $420,000 (50%). This 50/50 cost-sharing arrangement is typical in transactions where the RWI Policy benefits both parties: Buyer obtains an additional, well-capitalized source of recovery for indemnification claims beyond the escrow and the cap, while Seller benefits from the reduced likelihood that Buyer will pursue direct claims against Seller or draw on the escrow for covered matters. The premium cost-sharing also reflects the economic reality that the RWI Policy was a component of the overall deal construct — Seller's agreement to share in the premium cost was part of the negotiation that produced the 18-month survival period, 20% cap, and two-tranche escrow release.
Seller's $420,000 share of the RWI premium is treated as a transaction cost and is reflected in the closing funds flow, reducing the net cash proceeds received by Seller at closing.
E. Coordination Between RWI and Escrow
The interaction between the RWI Policy and the escrow mechanics is designed to minimize Seller's direct indemnification exposure:
During the Escrow Period (Closing through February 8, 2025). Section 10.8 of the APA requires Buyer to first tender indemnification claims to Apex Mutual under the RWI Policy before drawing on the escrow for covered matters. This "insurance-first" provision is a critical Seller protection that preserves the escrow balance and maximizes the likelihood that escrowed funds will be returned to Seller at the scheduled release dates. If Apex Mutual accepts and pays a claim, the escrow is not affected. If Apex Mutual denies a claim (e.g., due to a known-matters exclusion or a coverage dispute), Buyer may then seek recovery from the escrow, subject to the claim procedures and dispute resolution mechanisms described in Section VI.C above.
Post-Escrow Release (After February 8, 2025). Following the final release of escrowed funds, Buyer's sole recourse for covered claims is the RWI Policy (up to the $28,000,000 limit), and for uncovered claims (including known matters and fraud), direct claims against Seller (subject to the APA's post-survival limitations). For non-fundamental representation claims, the survival period will have expired by the time of the final escrow release, so no new claims may be asserted after that date. For Fundamental Representation claims, which survive for 60 months, Buyer retains recourse to the RWI Policy (which also covers Fundamental Representations for 60 months) and, for matters excluded from or exceeding RWI coverage, direct claims against Seller.
This coordination structure is expected to result in minimal or no actual draws on the escrow, which is a significant practical benefit to Seller and Pinnacle. The equity sponsor's interest in prompt return of sale proceeds to the fund — particularly in light of the fund's anticipated distribution timeline — is well-served by the combination of the two-tranche escrow release and the insurance-first requirement that diverts covered claims to Apex Mutual rather than to the escrow.
IX. Assumed Liabilities vs. Excluded Liabilities — Risk Boundary
A. Assumed Liabilities
Pursuant to Section 2.4 of the APA, Buyer assumes the following liabilities in connection with the acquisition of the OncuPath Business (the "Assumed Liabilities"):
(i) All trade payables and other current liabilities of the OncuPath Business arising or accruing in the ordinary course of business from and after the Closing Date;
(ii) All obligations arising under the Assumed Contracts from and after the Closing Date, including but not limited to: (a) the exclusive technology license agreement with Vantage Molecular Sciences, Inc. dated September 12, 2019 (as amended, the "Vantage License"); (b) all transferred customer and supplier contracts identified on Schedule 2.1(e) to the APA; and (c) the assigned leases for the premises located at 4820 Towne Centre Drive, San Diego, California (laboratory operations) and 925 Industrial Court, San Diego, California (warehouse and distribution);
(iii) All product warranty claims and product liability obligations for OncuPath assays shipped or distributed on or after the Closing Date; and
(iv) All other liabilities and obligations arising out of or relating to Buyer's ownership or operation of the OncuPath Business from and after the Closing Date.
Seller has no indemnification obligation with respect to the Assumed Liabilities. Any losses or claims arising from Assumed Liabilities are Buyer's sole responsibility, and Buyer has agreed to indemnify and hold harmless Seller with respect thereto under Section 10.3 of the APA.
B. Excluded Liabilities (Retained by Seller)
Section 2.5 of the APA identifies the following liabilities as "Excluded Liabilities," which are retained by Seller and are not assumed by Buyer:
(i) All liabilities of the OncuPath Business arising, accruing, or relating to the period prior to the Closing Date, including trade payables, accrued expenses, and other obligations that are attributable to the pre-closing operation of the OncuPath Business (except to the extent reflected as current liabilities in the closing working capital calculation);
(ii) Any litigation, claims, or proceedings pending as of the Closing Date, including the NovaBio patent infringement action and the wage-and-hour class action identified in the Disclosure Schedules;
(iii) All employee benefit obligations (including severance, COBRA, accrued paid time off, and pension or retirement plan obligations) with respect to the five (5) OncuPath employees who did not accept offers of employment from Buyer (of the 83 employees who received offers, 78 accepted and 5 declined). GDT retains all obligations with respect to the non-transferring employees;
(iv) All environmental liabilities at GDT facilities that are not being conveyed as part of the Purchased Assets, including any remediation, cleanup, or compliance obligations at GDT's corporate headquarters or other retained facilities;
(v) All pre-closing tax liabilities of GDT attributable to the OncuPath Business, including income taxes, employment taxes, sales and use taxes, and any other taxes arising from or related to the operation of the OncuPath Business prior to the Closing Date; and
(vi) All other liabilities and obligations of GDT that are not Assumed Liabilities.
Seller's indemnification obligations under Section 10.2 of the APA encompass the Excluded Liabilities to the extent that any Excluded Liability is inadvertently transferred to, imposed upon, or otherwise affects Buyer in connection with the transaction. This creates a contractual backstop ensuring that if an Excluded Liability "follows" the assets to Buyer notwithstanding the parties' intention to retain such liability with Seller, Buyer has recourse to Seller's indemnification for the resulting Losses.
The clear delineation of Assumed and Excluded Liabilities is fundamental to the risk boundary between the parties. Seller should ensure that the closing funds flow and working capital calculations accurately reflect the allocation of pre-closing and post-closing liabilities, as any misallocation could give rise to indemnification claims or working capital adjustment disputes.
X. Working Capital Adjustment — Interaction with Indemnification
The APA includes a customary post-closing working capital adjustment mechanism, the key terms of which are as follows:
• Target Net Working Capital ("NWC"): $6,800,000, determined by reference to the carve-out financial statements of the OncuPath Business prepared by Haverford & Lane LLP for the twelve-month period ended December 31, 2022, and the stub period ended March 31, 2023.
• Collar: ±$350,000. No purchase price adjustment is made if final NWC falls within the collar range of $6,450,000 to $7,150,000. If final NWC is above $7,150,000, the purchase price is increased by the amount of the excess. If final NWC is below $6,450,000, the purchase price is decreased by the amount of the shortfall.
• True-Up Deadline: The final NWC determination must be completed within ninety (90) days of the Closing Date, or by November 6, 2023.
• Dispute Resolution: If the parties cannot agree on the final NWC within thirty (30) days of Seller's delivery of an objection notice, the disputed items are submitted to a mutually agreed independent accounting firm for binding determination. The costs of the independent accounting firm are allocated between the parties based on the relative success of their respective positions.
Interaction with Indemnification Framework. The NWC adjustment is expressly characterized in the APA as a price adjustment mechanism and is not an indemnification claim. Accordingly, the NWC adjustment is carved out from the indemnification cap, basket, and de minimis threshold. This means that a dollar-for-dollar adjustment to the purchase price based on the final NWC calculation is not subject to the $1,400,000 basket, the $75,000 de minimis, or the $28,000,000 cap. This carve-out is standard and reflects the fundamental distinction between purchase price mechanics (which are designed to ensure that Buyer pays, and Seller receives, the appropriate price based on the financial condition of the business at closing) and indemnification (which addresses breaches of representations, warranties, and covenants).
Risk Note. Working capital disputes are common in carve-out transactions due to the inherent complexity of allocating shared costs, intercompany charges, and corporate overhead between the divested business and the retained business. In the OncuPath transaction, several line items in the NWC calculation involve allocations of shared IT infrastructure costs, shared facility expenses, and centralized HR/payroll costs that were historically borne at the GDT corporate level and allocated to the OncuPath Business based on methodologies that may be subject to differing interpretations. Haverford & Lane's preparation of the carve-out financial statements and its involvement in the final closing balance sheet provide Seller with a credible, independent basis for its NWC position in the event of a dispute. Nevertheless, Seller should anticipate the possibility of a working capital dispute and ensure that all allocation methodologies are well-documented and consistent with the accounting principles specified in the APA (which reference GAAP applied on a basis consistent with the preparation of the carve-out financial statements).
XI. Benchmarking Against Comparable Biotech Asset Divestitures
A. Methodology. To assess the market-consistency and relative favorability of the indemnification package negotiated in the GDT/Meridian APA, we reviewed publicly available data (including SEC filings, industry surveys published by the American Bar Association's Private Target Mergers & Acquisitions Deal Points Study, and the Cascade Advisory Group M&A Deal Terms Study) and proprietary deal databases maintained by Calderwood & Harkness for fifteen (15) comparable biotech and diagnostics asset divestitures completed between 2021 and 2023 in the $100 million to $250 million range. The detailed results of this survey are set forth in Appendix A. The following key indemnification metrics were compared: indemnification cap as a percentage of deal value, survival period for general and fundamental representations, basket type (tipping vs. true deductible) and amount as a percentage of deal value, de minimis threshold, escrow amount as a percentage of deal value, RWI usage and policy limits, and escrow release structure.
B. Summary Comparison Table
The following table summarizes the benchmarking analysis:
C. Overall Assessment
The negotiated indemnification package is well-positioned from Seller's perspective. The most significant Seller-favorable features are: (a) the 18-month general survival period, which is at the shortest end of the observed market range and provides a compressed window for Buyer to assert claims; (b) the two-tranche escrow release, which accelerates the return of $7,000,000 to Seller at the 12-month mark rather than requiring Seller to wait until survival expiration; and (c) the buyer-side RWI Policy, which serves as Buyer's primary recourse for covered claims and reduces the practical likelihood that Buyer will pursue direct claims against Seller or the escrow.
The 20% indemnification cap, while at the upper end of the market range, is substantially mitigated by the RWI Policy. Because Buyer is contractually required to tender covered claims to Apex Mutual before seeking recovery from Seller, the effective cap from Seller's perspective is functionally lower than 20% for the vast majority of potential claims. The 1.0% tipping basket and $75,000 de minimis threshold are within market norms and provide reasonable first-dollar protection for Seller.
Taken as a whole, the indemnification package reflects a balanced outcome that is consistent with — and in several respects superior to — the indemnification terms observed in comparable biotech and diagnostics asset divestitures in this size range.
XII. Seller-Specific Risk Considerations
A. Carve-Out Complexity
The OncuPath Business is being carved out of GDT's broader operations, which introduces a number of complexities that could give rise to post-closing indemnification claims or disputes. During the pre-closing period and for up to nine (9) months following the Closing, GDT will provide Meridian with certain transitional support services pursuant to the Transition Services Agreement (the "TSA"), including IT infrastructure and systems support, HR and payroll administration, facilities management, and shared laboratory equipment access. Services under the TSA are provided at cost plus a five percent (5%) administrative markup.
The TSA creates potential friction points that could give rise to breach-of-covenant claims under the APA. In particular, disputes may arise regarding: (a) the quality or timeliness of services provided; (b) the methodology for calculating "cost" and the application of the 5% markup; (c) allocation of shared expenses between the OncuPath Business and GDT's retained operations; and (d) the timeline and process for transitioning services to Meridian's own systems and personnel.
Recommendation: Seller should implement strict internal tracking of all TSA costs, service levels, and performance metrics from the inception of the TSA. Detailed contemporaneous records will be essential to defending against any post-closing claims that GDT failed to perform its TSA obligations in a commercially reasonable manner or that GDT overcharged for transition services.
B. Regulatory Risk
The Purchased Assets include three FDA-cleared 510(k) companion diagnostic assays (K201847, K193215, and K210562) and a pending PMA supplement (P230014) for the OncuPath-HER3™ companion diagnostic assay. Additionally, the OncuPath laboratory operations are conducted under CLIA certificate 05D2178493. Post-closing regulatory issues relating to pre-closing manufacturing, marketing, or laboratory practices could give rise to indemnification claims. Potential scenarios include:
(i) FDA warning letters or inspection findings referencing pre-closing manufacturing practices or quality system deficiencies;
(ii) Product recalls or field safety corrective actions for assays manufactured and shipped prior to closing;
(iii) CMS enforcement actions related to pre-closing laboratory testing practices or CLIA compliance; and
(iv) State regulatory actions in any of the states in which the OncuPath Business holds clinical laboratory permits.
Mitigation: Seller has made comprehensive regulatory disclosures in Schedules 3.15 and 3.16 of the Disclosure Schedules, including a complete list of FDA clearances and submissions, CLIA certificates and permits, and a summary of the most recent FDA and CLIA inspection results. The 18-month general survival period limits the window during which Buyer may assert claims based on pre-closing regulatory matters (other than those captured by the Fundamental Representations or the 36-month Environmental Representations survival). Seller's regulatory compliance team should ensure that all pre-closing regulatory filings, inspection records, and corrective action plans are comprehensive and accurately reflected in the Disclosure Schedules.
C. Intellectual Property
The transfer of intellectual property is a critical component of the transaction. The Purchased Assets include 14 issued U.S. patents, 7 pending patent applications, and 3 registered trademarks, as well as associated trade secrets, know-how, and proprietary data. The IP representations in the APA (Section 3.10) address ownersh

MEMORANDUM

PRIVILEGED & CONFIDENTIAL ATTORNEY WORK PRODUCT

Record

Parties

Dates

Amounts